Dmitry Balyasny’s Apogee Therapeutics APGE Stock Holding History

Dmitry Balyasny’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.4M	Buy	+500,000	New	+$45M	0.08%	285

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Dmitry Balyasny's APGE Position: Q2 2026 in Review

Dmitry Balyasny increased its Apogee Therapeutics (APGE) stake by 280% in Q2 2026, buying an estimated $110M and bringing the position to 1,665,102 shares worth $221M. The position accounts for 0.28% of the portfolio, ranked #58.

Dmitry Balyasny first reported a position in APGE in Q1 2024 and has held it in 6 quarters since. 285 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Dmitry Balyasny held 1,665,102 shares of Apogee Therapeutics worth $221M as of Q2 2026.
Dmitry Balyasny bought 1,226,448 Apogee Therapeutics shares in Q2 2026, an estimated $110M.
Apogee Therapeutics made up 0.28% of Dmitry Balyasny's portfolio in Q2 2026, its #58 holding.
Dmitry Balyasny first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 6 quarters since.
285 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.